Patents by Inventor Anna Quattropani

Anna Quattropani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210186958
    Abstract: Compounds of formula (I), wherein A, R, W, Q, n and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 24, 2021
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Patent number: 10995090
    Abstract: Compounds of formula (I), wherein R?, R?, R, X, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: May 4, 2021
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Publication number: 20210077488
    Abstract: Compounds of formula (I), wherein A, R, W, Q, L, n and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 18, 2021
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Publication number: 20200385375
    Abstract: The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.
    Type: Application
    Filed: May 18, 2020
    Publication date: December 10, 2020
    Applicant: Asceneuron SA
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI, Dawn V. TORONTO, David Malcolm CROWE
  • Publication number: 20200289516
    Abstract: Compounds of formula (I), wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: August 24, 2017
    Publication date: September 17, 2020
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Patent number: 10696690
    Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: June 30, 2020
    Assignee: Ares Trading S.A.
    Inventors: Anna Quattropani, Dominique Swinnen
  • Patent number: 10696668
    Abstract: The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: June 30, 2020
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Dawn V. Toronto, David Malcolm Crowe
  • Publication number: 20200155515
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as preterm labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: January 27, 2020
    Publication date: May 21, 2020
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL, Ernest LOUMAYE, Oliver POHL, Jean-Pierre GOTTELAND
  • Patent number: 10556902
    Abstract: Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: February 11, 2020
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Patent number: 10555934
    Abstract: The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 11, 2020
    Assignee: ObsEva S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel, Ernest Loumaye, Oliver Pohl, Jean-Pierre Gotteland
  • Publication number: 20200002326
    Abstract: Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: August 24, 2017
    Publication date: January 2, 2020
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Publication number: 20190388415
    Abstract: Compounds of formula (I), wherein R?, R?, R, X, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 26, 2019
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Publication number: 20190367533
    Abstract: The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.
    Type: Application
    Filed: May 15, 2019
    Publication date: December 5, 2019
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Patent number: 10344021
    Abstract: The invention relates to a process for preparing either enantiomer of a compound of formula (I), wherein X, Y and n have the meaning given in claim 1, with high enantiomeric excess (e.e.), by chiral resolution in the presence of a non-racemic, chiral acid.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 9, 2019
    Assignee: Asceneuron S A
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Johannes Nicolaas Koek
  • Patent number: 10336775
    Abstract: The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: July 2, 2019
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Publication number: 20190194151
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorph s thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL
  • Patent number: 10259795
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Merck Serono S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel
  • Publication number: 20190062316
    Abstract: The invention relates to a process for preparing either enantiomer of a compound of formula (I), wherein X, Y and n have the meaning given in claim 1, with high enantiomeric excess (e.e.), by chiral resolution in the presence of a non-racemic, chiral acid.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 28, 2019
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI, Johannes Nicolaas KOEK
  • Publication number: 20190055239
    Abstract: Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 21, 2019
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Publication number: 20190055233
    Abstract: The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 21, 2019
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI, Dawn V. TORONTO, David Malcolm CROWE